Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2017 | 1 |
2019 | 1 |
2022 | 2 |
2023 | 1 |
2024 | 2 |
Search Results
7 results
Results by year
Filters applied: . Clear all
It looks like you are searching for an author.
Results are currently sorted by Best Match. To see the newest results first,
change the sort order to Most Recent.
Page 1
AURORA: A New Dawn.
Clin Infect Dis. 2024 Apr 4:ciae114. doi: 10.1093/cid/ciae114. Online ahead of print.
Clin Infect Dis. 2024.
PMID: 38571316
No abstract available.
Retrospective chart review of transplant recipients with cytomegalovirus infection who received maribavir in the Phase 3 SOLSTICE trial: Data at 52 weeks post-maribavir treatment initiation.
Bassel M, Romanus D, Bo T, Sundberg AK, Okala S, Hirji I.
Bassel M, et al. Among authors: bo t.
Antivir Ther. 2023 Oct;28(5):13596535231195431. doi: 10.1177/13596535231195431.
Antivir Ther. 2023.
PMID: 37657421
Free article.
Item in Clipboard
Drug Resistance Mutations and Associated Phenotypes Detected in Clinical Trials of Maribavir for Treatment of Cytomegalovirus Infection.
Chou S, Song K, Wu J, Bo T, Crumpacker C.
Chou S, et al. Among authors: bo t.
J Infect Dis. 2022 Sep 4;226(4):576-584. doi: 10.1093/infdis/jiaa462.
J Infect Dis. 2022.
PMID: 32726419
Free PMC article.
Item in Clipboard
Recommendations on clinical trial design for treatment of Mucopolysaccharidosis Type III.
Ghosh A, Shapiro E, Rust S, Delaney K, Parker S, Shaywitz AJ, Morte A, Bubb G, Cleary M, Bo T, Lavery C, Bigger BW, Jones SA.
Ghosh A, et al. Among authors: bo t.
Orphanet J Rare Dis. 2017 Jun 26;12(1):117. doi: 10.1186/s13023-017-0675-4.
Orphanet J Rare Dis. 2017.
PMID: 28651568
Free PMC article.
Item in Clipboard
Cost-effectiveness of maribavir versus conventional antiviral therapies for post-transplant refractory cytomegalovirus infection with or without genotypic resistance: A US perspective.
Schultz BG, Kotton CN, Jutlla G, Ressa R, de Lacey T, Chowdhury E, Bo T, Fenu E, Gelone DK, Poirrier JE, Amorosi SL.
Schultz BG, et al. Among authors: bo t.
J Med Virol. 2024 Apr;96(4):e29609. doi: 10.1002/jmv.29609.
J Med Virol. 2024.
PMID: 38647051
Item in Clipboard
Evaluation of treatment patterns, healthcare resource utilization, and costs among patients receiving treatment for cytomegalovirus following allogeneic hematopoietic cell or solid organ transplantation.
Cheng WY, Avery RK, Thompson-Leduc P, Cheung HC, Bo T, Duh MS, Hirji I.
Cheng WY, et al. Among authors: bo t.
J Med Econ. 2022 Jan-Dec;25(1):367-380. doi: 10.1080/13696998.2022.2046388.
J Med Econ. 2022.
PMID: 35240904
Free article.
Item in Clipboard
Novel UL97 drug resistance mutations identified at baseline in a clinical trial of maribavir for resistant or refractory cytomegalovirus infection.
Chou S, Wu J, Song K, Bo T.
Chou S, et al. Among authors: bo t.
Antiviral Res. 2019 Dec;172:104616. doi: 10.1016/j.antiviral.2019.104616. Epub 2019 Sep 27.
Antiviral Res. 2019.
PMID: 31568799
Free PMC article.
Clinical Trial.
Item in Clipboard
Cite
Cite